Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours
Condition(s)
Bile Duct Cancer (Cholangiocarcinoma), Lung Cancer (NSCLC), Pancreatic Cancer, Urothelial Cancer
Molecular Target(s)
MDM2
Drug Classification(s)
Molecular Targeted Therapy
Agents(s)
Zenocutuzumab, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3
Phase(s)
II
Mechanism of Action
BI 907828 is a so-called MDM2 inhibitor
Purpose
Location
Mary Crowley Cancer Research - Medical City Dallas
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.
7777 Forest Lane,
Building C-707
Dallas, TX 75230
972.566.3000